Bortecine Bortezomib Injection I.P. 2mg

About Bortecine Bortezomib Injection I.P. 2mg

Bortecine Bortezomib Injection I.P. 2 mg is a medication used primarily in the treatment of certain types of cancer. The active ingredient in Bortecine is Bortezomib, which is a proteasome inhibitor. It works by interfering with the function of proteasomes, which are responsible for breaking down proteins in cells. By inhibiting this process, Bortezomib causes cancer cells to accumulate damaged proteins, leading to their death.

Bortezomib is commonly used for the treatment of:

• Multiple myeloma (a cancer of plasma cells in the bone marrow)
• Mantle cell lymphoma (a type of non-Hodgkin lymphoma)

Key Points about Bortecine (Bortezomib) Injection:

• Dosage: The dose and frequency of Bortezomib injections depend on the condition being treated and the patient's individual response. It is often administered intravenously or subcutaneously, usually in cycles.

• Side Effects: Some potential side effects of Bortezomib include nausea, fatigue, diarrhea, low blood cell counts (which can lead to an increased risk of infection or bleeding), peripheral neuropathy (nerve damage causing tingling or numbness in the hands and feet), and a risk of heart or liver problems.

• Precautions: Patients with pre-existing liver issues, low blood counts, or neuropathy should inform their doctor before starting treatment. Close monitoring during treatment is essential to manage side effects and adjust dosages accordingly.

• Administration: Bortezomib is usually given under the supervision of a healthcare professional. It is typically administered in cycles, with periods of treatment followed by rest periods to allow the body to recover.

If you or someone you know is undergoing treatment with Bortecine, its essential to follow the medical teams guidance and attend regular check-ups to monitor for any adverse effects. 

Effective Treatment for Multiple Myeloma and Mantle Cell Lymphoma

Bortecine Bortezomib Injection I.P. 2mg is tailored to manage and slow the progression of multiple myeloma and mantle cell lymphoma. Through proteasome inhibition, it disrupts cancer cell growth, offering proven efficacy as part of combination chemotherapy regimens. Its use is supported by robust clinical evidence and regulated dosing protocols.


Safe, Precise, and Easy-to-Use Dosage Form

Bortecine's lyophilized powder format ensures product stability and accurate reconstitution for either intravenous or subcutaneous injection. Single-use glass vials minimize contamination risks and allow for efficient preparation in clinical practice. The white to off-white powder reconstitutes quickly, enabling timely administration by medical staff.


Handling, Storage, and Administration

To maintain potency, Bortecine should be stored refrigerated at 2C-8C and protected from light. It must be administered in a hospital or clinical setting by qualified professionals, as per physician instructions, following all safety and handling procedures. The medication is supplied with a clear expiry date and is intended for one-time use.